Perceptive Advisors LLC Has $70.77 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Perceptive Advisors LLC boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 135.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,434,033 shares of the biotechnology company’s stock after purchasing an additional 4,271,504 shares during the quarter. BioCryst Pharmaceuticals comprises 1.4% of Perceptive Advisors LLC’s holdings, making the stock its 21st largest holding. Perceptive Advisors LLC’s holdings in BioCryst Pharmaceuticals were worth $70,772,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of BCRX. Phocas Financial Corp. acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $1,956,000. Aberdeen Group plc bought a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $7,126,000. Vanguard Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the period. BNP Paribas Financial Markets boosted its position in shares of BioCryst Pharmaceuticals by 21.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after purchasing an additional 448,436 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of BioCryst Pharmaceuticals by 17.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 2,230,105 shares of the biotechnology company’s stock worth $21,231,000 after purchasing an additional 325,959 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 2.8%

Shares of BioCryst Pharmaceuticals stock opened at $8.98 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.22. The firm has a market capitalization of $2.28 billion, a P/E ratio of -5.04 and a beta of 0.55. The business has a fifty day simple moving average of $9.30 and a two-hundred day simple moving average of $8.63.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 earnings per share. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BCRX shares. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Cantor Fitzgerald raised their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.80.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.